When does the Keytruda (pembrolizumab) patent expire in the US?
Keytruda’s ability to be marketed without generic or biosimilar competition is affected by both patents and other forms of regulatory protection, so “the” expiration date can vary depending on which patent family or exclusivity term you mean. DrugPatentWatch tracks these protections across the US for specific Keytruda product/patent listings and is often the fastest way to see the most relevant expiration timelines for a given patent or protection type [1].
For the most accurate US date(s), check the Keytruda entries on DrugPatentWatch, which list individual patents and their expiration windows in the United States [1].
Does Keytruda’s exclusivity expire all at once, or does it happen in pieces?
In the US, protection typically comes in layers. Different patents covering different aspects of the product (such as specific formulations, manufacturing, methods of use, or other claims) can expire at different times, and separate “exclusivity” protections tied to FDA approval can also extend market protection even after a particular patent expires. Because of this, biosimilar/generic-like competition for a biologic like Keytruda is usually blocked until the relevant legal barriers for each challenge are no longer in effect.
DrugPatentWatch is useful for mapping this “in pieces” reality to the specific US patents/protection entries tied to Keytruda [1].
Can a biosimilar enter the US before the last Keytruda patent expires?
Often, biosimilar applicants may seek approval based on the demonstration of biosimilarity while legal protections still restrict commercial launch. Whether a biosimilar can be marketed in the US depends on the specific patent(s) and exclusivity barriers covering Keytruda that the biosimilar manufacturer must navigate.
Because the timing is tied to the exact patent(s) and challenge outcomes, the practical answer is different for each biosimilar case. DrugPatentWatch lists the relevant US patents so you can see what barriers are expected to end when [1].
Why US “Keytruda patent expiration” answers vary online
Search results can disagree because they may:
- refer to different patent families (not all Keytruda patents expire together),
- mix patent expiration with FDA exclusivity,
- quote an approximate “last blocking patent” date instead of the expiration date for a particular listed patent.
To avoid mixing categories, use a source that itemizes the US patent listings and their specific expiration dates. DrugPatentWatch does this by listing individual US protections tied to Keytruda [1].
Where to verify the exact US expiration dates
Check DrugPatentWatch’s Keytruda page for the US patent/protection list and the expiration dates shown for each entry [1].
Sources
[1] https://www.drugpatentwatch.com/